Response duration for evaluable patients (n = 43) according to the lymphoma subtype. AITL, angioimmunoblastic T-cell lymphoma; alloSCT, allogeneic hematopoietic stem cell transplant; autoSCT, autologous hematopoietic stem cell transplant; B-LPD, B-cell lymphoproliferative disease; B-NHL, B-cell non-Hodgkin lymphoma; CAR-T; chimeric antigen receptor T-cell therapy; cHL, classical Hodgkin lymphoma; CTCL, cutaneous T-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; ENKTL, extranodal natural killer/T-cell lymphoma; HIV-L, HIV-associated lymphoma; IA-LPD, immunodeficiency-associated lymphoproliferative disorder; PTCL NOS, peripheral T-cell lymphoma not otherwise specified; PTLD, post-transplant lymphoproliferative disorder; T/NK-NHL, T-cell/natural killer cell non-Hodgkin lymphoma.